From the Food and Drug Administration.
Nightingale
S L
SL
Office of Health Affairs, FDA, Rockville, MD 20857.
D000328:Adult; D001386:Azides / Q000009:adverse effects*; D004348:Drug Labeling; D005260:Female; D015248:Gemfibrozil / Q000627:therapeutic use*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011861:Radiography, Dental / Q000706:statistics & numerical data*; D006435:Renal Dialysis / Q000009:adverse effects*; D019810:Sodium Azide
D001386:Azides; D019810:Sodium Azide; D015248:Gemfibrozil